Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Takuo Nambu"'
Autor:
Shin Yonemitsu, Seiji Muro, Takuo Nambu, Sumio Saito, Shogo Oki, Takeshi Usui, Yuki Matsuda, Tomoko Kato, Yuki Mochida, Takaaki Murakami, Akio Nakajima
Publikováno v:
Internal Medicine. 54:2475-2481
A 35-year-old obese diabetic man presented with recurrent primary hyperparathyroidism during a three-year outpatient follow-up. He was clinically diagnosed with multiple endocrine neoplasia type 1 (MEN1) due to the presence of a pituitary adenoma and
Autor:
Yuki Matsuda, Takuo Nambu, Seiji Muro, Shogo Oki, Koji Matsuo, Shin Yonemitsu, Yuki Morimoto, Takaaki Murakami
Publikováno v:
Internal Medicine. 53:743-747
We herein describe the case of a woman with pseudohypoparathyroidism (PHP) type II. She had a history of subtotal thyroidectomy against Graves' disease without levothyroxine supplementation and presented with stiffness, numbness and muscle cramps. He
Autor:
Tomonobu Hatoko, Takaaki Murakami, Seiji Muro, Yuki Matsuda, Shin Yonemitsu, Koji Matsuo, Shogo Oki, Takuo Nambu
Publikováno v:
Endocrine Journal. 61:773-779
Central diabetes insipidus (CDI) is a rare disease characterized by polyuria and polydipsia. Patients with CDI have been successfully treated with desmopressin administered either by intranasal instillation or oral tablets. Recently, a desmopressin o
Publikováno v:
Journal of Diabetes Investigation
Aims/Introduction Liraglutide, a glucagon-like peptide-1 receptor agonist, is expected to provide a new treatment option for diabetes. However, the suitable timing of liraglutide administration in type 2 diabetic patients has not yet been clarified.
Autor:
Masako Miura, Akihiro Yasoda, Takuo Nambu, Kazuwa Nakao, Seiji Muro, Ryota Izumi, Yuya Shinoto, Shin Yonemitsu, Yugo Kanai, Shogo Oki, Naotetsu Kanamoto, Koji Matsuo, Hiroshi Arai, Keita Mori
Publikováno v:
Diabetes Research and Clinical Practice. 96:326-330
Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus and is caused by insulin insufficiency. Hypothermia is defined as a core temperature of less than 35°C and is sometimes accompanied by DKA. We report two pat
Autor:
Takaaki, Murakami, Takeshi, Usui, Akio, Nakajima, Yuki, Mochida, Sumio, Saito, Takuo, Nambu, Tomoko, Kato, Yuki, Matsuda, Shin, Yonemitsu, Seiji, Muro, Shogo, Oki
Publikováno v:
Internal medicine (Tokyo, Japan). 54(19)
A 35-year-old obese diabetic man presented with recurrent primary hyperparathyroidism during a three-year outpatient follow-up. He was clinically diagnosed with multiple endocrine neoplasia type 1 (MEN1) due to the presence of a pituitary adenoma and
Autor:
Masato Taki, Tomoko Kato, Seiji Muro, Yuki Matsuda, Shin Yonemitsu, Takuo Nambu, Takaaki Murakami, Tomoko Wakasa, Shogo Oki
Publikováno v:
Internal medicine (Tokyo, Japan). 54(7)
A 55-year-old man presented with a rapidly enlarging thyroid. He had been diagnosed with lung adenocarcinoma nine months earlier. Computed tomography (CT) and ultrasound (US) detected reticular cord-like structures, but no nodules, in the thyroid. A
Autor:
Seiji Muro, Takaaki Murakami, Tomoko Kato, Takuo Nambu, Yuki Matsuda, Shin Yonemitsu, Shogo Oki
Publikováno v:
The Tohoku journal of experimental medicine. 235(4)
The combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and a long-acting insulin analogue is widely used in clinical practice. However, some patients fail to achieve lower postprandial hyperglycemia. Mitiglinide, a short-acting insulinotropic
Autor:
Takaaki Murakami, Seiji Muro, Masanori Yoshida, Tomoko Funazo, Takuo Nambu, Koji Matsuo, Shogo Oki, Shin Yonemitsu, Yuki Matsuda
Publikováno v:
Internal medicine (Tokyo, Japan). 53(19)
We herein describe two patients with a prolonged disturbance of consciousness due to severe hypophosphatemia. Case one presented with pneumococcal infection and acute exacerbation of chronic obstructive pulmonary disease and asthma. Case two presente
Publikováno v:
Internal medicine (Tokyo, Japan). 52(1)
Glucocorticoid-induced hyperglycemia is common in patients with or without known diabetes mellitus. Exenatide, a glucagon-like peptide-1 receptor agonist, improves glycemic control without causing weight gain or hypoglycemia and is currently widely u